title: Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.
abstract: We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility.
authors.affiliation: Evanston Northwestern Healthcare, IL 60201, USA. pgavin@enh.org
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Gavin
authors.forename: Mira T
authors.initials: MT
authors.lastname: Suseno
authors.forename: Richard B
authors.initials: RB
authors.lastname: Thomson
authors.forename: J Michael
authors.initials: JM
authors.lastname: Gaydos
authors.forename: Carl L
authors.initials: CL
authors.lastname: Pierson
authors.forename: Diane C
authors.initials: DC
authors.lastname: Halstead
authors.forename: Jaber
authors.initials: J
authors.lastname: Aslanzadeh
authors.forename: Stephen
authors.initials: S
authors.lastname: Brecher
authors.forename: Coleman
authors.initials: C
authors.lastname: Rotstein
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Brossette
authors.forename: Lance R
authors.initials: LR
authors.lastname: Peterson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D005260:Female; D006801:Humans; D041121:Klebsiella oxytoca / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010878:Piperacillin / Q000494:pharmacology / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology; D065093:beta-Lactamase Inhibitors
chemical_list: D000900:Anti-Bacterial Agents; D065093:beta-Lactamase Inhibitors; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin